57 research outputs found
Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes
Background: In the central nervous system, glial cells provide metabolic and trophic support to neurons and respond to protracted stress and insults by up-regulating inflammatory processes. Reactive astrocytes and microglia are associated with the pathophysiology of neuronal injury, neurodegenerative diseases and major depression, in both animal models and human brains. Several studies have reported clear anti-inflammatory effects of anti-depressant treatment on astrocytes, especially in models of neurological disorders. Trazodone (TDZ) is a triazolopyridine derivative that is structurally unrelated to other major classes of antidepressants. Although the molecular mechanisms of TDZ in neurons have been investigated, it is unclear whether astrocytes are also a TDZ target. Methods: The effects of TDZ on human astrocytes were investigated in physiological conditions and following inflammatory insult with lipopolysaccharide (LPS) and tumour necrosis factor-aα (TNF-aα). Astrocytes were assessed for their responses to pro-inflammatory mediators and cytokines, and the receptors and signalling pathways involved in TDZ-mediated effects were evaluated. Results: TDZ had no effect on cell proliferation, but it decreased pro-inflammatory mediator release and modulated trophic and transcription factor mRNA expression. Following TDZ treatment, the AKT pathway was activated, whereas extracellular signal-regulated kinase and c-Jun NH2-terminal kinase were inhibited. Most importantly, a 72-h TDZ pre-treatment before inflammatory insult completely reversed the anti-proliferative effects induced by LPS-TNF-aα. The expression or the activity of inflammatory mediators, including interleukin-6, c-Jun NH2-terminal kinase and nuclear factor ΚB, were also reduced. Furthermore, TDZ affected astrocyte metabolic support to neurons by counteracting the inflammation-mediated lactate decrease. Finally, TDZ protected neuronal-like cells against neurotoxicity mediated by activated astrocytes. These effects mainly involved an activation of 5-HT1A and an antagonism at 5-HT2A/C serotonin receptors. Fluoxetine, used in parallel, showed similar final effects nevertheless it activates different receptors/intracellular pathways. Conclusions: Altogether, our results demonstrated that TDZ directly acts on astrocytes by regulating intracellular signalling pathways and increasing specific astrocyte-derived neurotrophic factor expression and lactate release. TDZ may contribute to neuronal support by normalizing trophic and metabolic support during neuroinflammation, which is associated with neurological diseases, including major depression
Anti-Prion Activity of Brilliant Blue G
BACKGROUND: Prion diseases are fatal neurodegenerative disorders with no effective therapy currently available. Accumulating evidence has implicated over-activation of P2X7 ionotropic purinergic receptor (P2X7R) in the progression of neuronal loss in several neurodegenerative diseases. This has led to the speculation that simultaneous blockade of this receptor and prion replication can be an effective therapeutic strategy for prion diseases. We have focused on Brilliant Blue G (BBG), a well-known P2X7R antagonist, possessing a chemical structure expected to confer anti-prion activity and examined its inhibitory effect on the accumulation of pathogenic isoforms of prion protein (PrPres) in a cellular and a mouse model of prion disease in order to determine its therapeutic potential. PRINCIPAL FINDINGS: BBG prevented PrPres accumulation in infected MG20 microglial and N2a neural cells at 50% inhibitory concentrations of 14.6 and 3.2 µM, respectively. Administration of BBG in vivo also reduced PrPres accumulation in the brains of mice with prion disease. However, it did not appear to alleviate the disease progression compared to the vehicle-treated controls, implying a complex role of P2X7R on the neuronal degeneration in prion diseases. SIGNIFICANCE: These results provide novel insights into the pathophysiology of prion diseases and have important implications for the treatment
Apurinic/apyrimidinic endonuclease 1 is a key modulator of aluminum-induced neuroinflammation
Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes
Evaluating the interaction between early postnatal inflammation and maternal care in the programming of adult anxiety and depression-related behaviors
The perinatal development of the nervous system is influenced by different external and internal stimuli. Previous data show that maternal care and perinatal inflammation can induce long-term changes in anxiety- and depression-related behavior. Our hypothesis is that both maternal care and perinatal inflammation act through interacting biological pathways to program adult behavior. To evaluate this interaction, we combined a protocol of maternal care variation in mice (C57BL/6JĂ—BALB/c reciprocal
F1 offspring) with the administration of bacterial wall lipopolysaccharide (LPS) at a previously reported sensitive development age (postnatal day 3, P3). The analysis of maternal behavior revealed that pups from C57BL/6J dams received more maternal attention than those taken care by BALB/c dams. Pups receiving LPS at P3 showed an acute corticosterone response, and a dose-dependent desensitization of this hormonal response when challenged with LPS at adulthood. We analyzed adult behavior on 6 highly validated tests and found an interaction between maternal care and early postnatal LPS on 7
anxiety-related behaviors in 4 different tests. In particular, early postnatal LPS treatment resulted in higher anxiety-related behavior when administered to females receiving more maternal care (C57 pedigree), but reduced depression-related behavior in males of the same pedigree. These results suggest that specific coping strategies are sensitive to maternal care and/or postnatal inflammation programming of adult anxiety- and depression-related behaviors, suggesting that both divergent and convergent mechanisms participate in this programming
Trick or treat? neurodevelopmental consequences of pharmacotherapy for affective disorders
Trained innate immunity:a salient factor in the pathogenesis of neuroimmune psychiatric disorders
Sociability deficits after prenatal exposure to valproic acid are rescued by early social enrichment
Upregulation of NAD(P)H:Quinone Oxidoreductase (NQO1) in Glial Cells of 6-Hydroxydopamine-Lesioned Substantia Nigra in the Rat
- …